WO2022045138A1 - Composition pour modifier l'occupation de la flore intestinale par de genres spécifiques de bactéries - Google Patents

Composition pour modifier l'occupation de la flore intestinale par de genres spécifiques de bactéries Download PDF

Info

Publication number
WO2022045138A1
WO2022045138A1 PCT/JP2021/030999 JP2021030999W WO2022045138A1 WO 2022045138 A1 WO2022045138 A1 WO 2022045138A1 JP 2021030999 W JP2021030999 W JP 2021030999W WO 2022045138 A1 WO2022045138 A1 WO 2022045138A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
daikenchuto
composition
intestinal flora
occupancy rate
Prior art date
Application number
PCT/JP2021/030999
Other languages
English (en)
Japanese (ja)
Inventor
克典 佐々木
明弘 山森
建吾 佐々木
大介 佐々木
昭彦 近藤
Original Assignee
住友化学株式会社
国立大学法人神戸大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 住友化学株式会社, 国立大学法人神戸大学 filed Critical 住友化学株式会社
Publication of WO2022045138A1 publication Critical patent/WO2022045138A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/758—Zanthoxylum, e.g. pricklyash
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger

Definitions

  • the present invention relates to a composition for increasing the occupancy rate of Bifidobacterium and the occupancy rate of Fusobacterium in the intestinal flora and decreasing the occupancy rate of Fusobacterium.
  • the intestinal flora refers to a group of bacteria (intestinal bacteria) existing in the intestine, and is also called an intestinal flora, microbiota, or microbiome.
  • various diseases such as diabetes, atopic eczema, and dementia, and the relationship between health conditions such as obesity and the intestinal flora have been reported, and are represented by lactic acid bacteria and bifidobacteria. It has been widely pointed out that it is important to improve the intestinal flora by foods such as probiotics and prebiotics typified by dietary fiber (Non-Patent Document 1).
  • Daikenchuto is a typical Chinese medicine prescription described in the Chinese Song dynasty medical book “Kinpou”, and has an intestinal motility-enhancing effect, an intestinal hyperkinetic inhibitory effect, an intestinal obstruction (ireus) -suppressing effect, and an intestinal tract. It is known to have an effect of increasing blood flow and an anti-inflammatory effect.
  • the knowledge about the effect of Daikenchuto on the human intestinal flora is extremely limited.
  • the inventors have obtained the finding that Daikenchuto extract can significantly increase the occupancy rate (%) of Gut microbiota in the intestinal flora (Patent Document 1). It is an object of the present invention to further investigate the effect of daikenchuto on a specific bacterial genus in the intestinal flora and to provide a composition having an advantageous effect on the intestinal flora.
  • Daikenchuto extract which is a Chinese herbal drug substance, occupies the occupancy rate of Bifidobacterium spp. In the intestinal flora and the genus Coprococcus. It was found that the occupancy rate of Fusobacterium can be increased and the occupancy rate of Fusobacterium can be decreased.
  • the present invention has been completed by further studies based on these findings, and has increased the occupancy rate of Bifidobacterium spp. And Coprococcus spp. In the intestinal flora, and has been completed. It provides a composition for reducing the occupancy rate of Fusobacterium.
  • the present invention is as follows.
  • composition [1] To increase the occupancy of Bifidobacterium and Coprococcus in the intestinal flora, including an effective amount of Daikenchuto extract, and to decrease the occupancy of Fusobacterium.
  • Composition [2] The composition according to [1], wherein the Daikenchuto extract is an extract of a raw material crude drug consisting of (1) Japanese pepper and / or Japanese pepper, (2) ginseng, and (3) dried ginger. [3] The composition according to [1] or [2], wherein the Daikenchuto extract is an extract of a crude drug as a raw material, which is an extract of water, ethanol, or a mixed solvent of water and ethanol.
  • the occupancy rate of Bifidobacterium and Coprococcus in the intestinal flora can be increased and the occupancy rate of Fusobacterium can be decreased. As a result, it improves the intestinal flora and has the effect of promoting health.
  • composition of the present invention a disease or a disease that can be treated, prevented or ameliorated by increasing the occupancy rate of Bifidobacterium spp., Increasing the occupancy rate of Coprococcus spp., And decreasing the occupancy rate of Fusobacterium spp. It can contribute to the prevention, treatment or amelioration of symptoms.
  • the composition of the present invention increases the occupancy rate of Bifidobacterium spp. And Coprococcus spp. In the intestinal flora, and contains Fusobacterium spp., Containing an effective amount of Daikenchuto extract. It is a composition for reducing the occupancy rate of.
  • Bifidobacterium is a general term for microorganisms belonging to the genus Bifidobacterium of the family Bifidobacterium, and Bifidobacterium inhabiting the human intestinal tract is Bifidobacterium.
  • Bifidobacterium bifidom, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium longum, Bifidobacterium longum, Bifidobacterium longum -Adolecentis (Bifidobacterium adolescentis) can be mentioned.
  • Bifidobacterium is known as a useful bacterium that decomposes sugar to produce lactic acid and acetic acid, and has an intestinal regulating effect, improvement of allergic symptoms such as pollinosis, anti-inflammatory effect, immunostimulatory effect, etc.
  • Various health benefits are known (eg, ScienceDirect overview, https://www.sciencedirect.com/topics/immunology-and-microbiology/bifidobacterium).
  • the genus Coccoccus is a general term for microorganisms belonging to the genus Lachnospiraceae, and a typical genus Coccus is Cporococcus eutactus.
  • the genus Coprococcus is a useful bacterium known as a butyric acid-producing bacterium, and is known to be involved in the suppression of colorectal cancer as a health effect. In addition, the production of butyric acid improves the intestinal environment (bad bacteria). (Suppression), immunostimulatory action, antiallergic, anti-inflammatory, and effects on diabetes are expected.
  • Fusobacterium genus is a general term for microorganisms belonging to the genus Fusobacterium of the family Fusobacterium, and a typical Fusobacterium genus is Fusobacterium nucleatum. Fusobacterium is also known as an oral bacterium, and is known to be associated with various diseases such as periodontal disease, Lemierre's syndrome, and skin ulcer, and also pointed out to be associated with ulcerative colitis and colorectal cancer. (For example, ScienceDirect overview, https://www.sciencedirect.com/topics/medicine-and-dentistry/fusobacterium).
  • Daikenchuto is described in the Chinese Song dynasty medical book “Kinpou”, and has an intestinal motility-enhancing effect, an intestinal hyperkinetic inhibitory effect, an intestinal obstruction (ireus) -suppressing effect, an intestinal blood flow increasing effect, an anti-inflammatory effect, etc.
  • Non-Patent Document 1 A typical Daikenchuto is a powdered extract of a mixed crude drug consisting of 2.0 g of Japanese pepper or Japanese pepper, 3.0 g of carrot, and 5.0 g of dried ginger. Examples thereof include powdered ginger containing about 8 times the amount of the extract.
  • Daikenchuto is a mixture of crude drugs consisting of (1) Japanese pepper or Japanese pepper, (2) carrots, and (3) Kankyo.
  • the extract of the mixture of (4) may further contain (4) Japanese pepper.
  • Those that do not contain glue candy are sometimes referred to as Koui Daikenchuto.
  • Sansho Zanthoxyli Piperiti Pericarpium
  • Sansho Zanthoxylum piperitum De Candle
  • the seeds separated from the peel are removed as much as possible. It can be prepared by collecting the fruit before ripening and drying it by removing the stalk and seeds as much as possible. It is added to the medicine to treat abdominal pain and bloating caused by cold. The main production areas are Japan and China.
  • examples of the original plant include Asakurazansho (Z. piperitum DC. F. inerme Makino) and grape sansho as variants of the original plant, and mature peels derived from these plants are also described in the present specification. Included in Sansho.
  • Zanthoxylum (Zanthoxyli Pericarpium) is a Rutaceae plant, Zanthoxylum bungeanum Maxim. Or Zanthoxylum schiniform Sieb. Et Zucc. It is the mature pericarp of the pericarp, and the seeds separated from the pericarp are removed as much as possible. It can be prepared by collecting the fruit before ripening and drying it by removing the stalk and seeds as much as possible. It is added to the medicine to treat abdominal pain and bloating caused by cold. The main production area is Sichuan province in China. In addition, as the original plant, Zanthoxylum armatum DC. Var. Subtrifoliatum Kitamura and the like are also mentioned, and mature pericarps derived from these plants are also included in the Chinese pepper in the present specification.
  • Ginseng (Ginseng Radix) is also called Korean ginseng, Korean ginseng, ginseng, white ginseng, Unshu ginseng, ginseng, and ginseng, which is an Araliaceae plant.
  • Ginseng CA Meyer Panax ginseng Nees roots excluding fine roots or lightly boiled. Ginseng promotes diminished metabolic function due to gastrointestinal weakness, chest stuffiness, loss of appetite, abdominal pain, diabetes, It is compounded in a medicinal method that improves fatigue, etc.
  • the main production areas are Japan, China and South Korea. After collecting roots and washing with water, ginseng roots and fine branch roots are removed, and ginseng (base of ginseng) ) Can be prepared by cutting it to an appropriate length, drying it in the shade, drying it in the sun, or drying it by heat.
  • Zingiberis Rhizoma Processum is a rhizome of ginger (Zingiber office Roscoe), which is a plant of the family Zingiberaceae, boiled or steamed. It is used as a medicine to improve vomiting, cough, diarrhea, cold hands and feet, and pain in the abdomen, lower back, and chest.
  • the main production area is China. It can be prepared by digging the rhizomes, removing sediment and fine roots, blanching or steaming, and then drying.
  • Koi corn (Zea mays Linne), cassava (Manihot esculenta Crantz), potato (Solanlum tuberosum Linne), sweet potato (Ipomoea batari) potato (Ipomoea battaris) P.
  • the removed seeds are hydrolyzed and saccharified, and the main component is maltose. It supplements and restores physical strength and energy, stops sputum and coughing, stimulates metabolism, and moisturizes the whole body under the control of the five organs.
  • the mass of (1) Sansho and / or Hansho is 1 part by mass
  • (2) Ginseng is 0.2 to 2.0 parts by mass
  • (3) Dried ginger is 1.0 to 3 parts. It is preferably 0.0 parts by mass, more preferably (2) 0.4 to 1.4 parts by mass of ginseng, and (3) 1.4 to 2.4 parts by mass of dried ginger. It is particularly preferable that 2) ginseng is 0.6 to 1.2 parts by mass and (3) dried ginger is 1.6 to 2.2 parts by mass.
  • the mass ratio of (1) Japanese pepper and / or Japanese pepper: (2) ginseng: (3) dried ginger may be 2: 3: 5 or 1: 1: 2.
  • Daikenchuto extract means an extract of a mixed crude drug consisting of (1) Japanese pepper and / or Japanese pepper, (2) carrot, and (3) crude drug as a raw material for dried ginger, and the extract thereof. It may be obtained by blending (4) Japanese pepper with the extract.
  • the crude drug extract is preferably extracted with a pharmaceutically acceptable aqueous solvent such as water (including hot water), ethanol or a mixed solvent of water and ethanol.
  • the extract may be produced by a known extraction method, and may be a general soft extract or extract granules.
  • the Daikenchuto extract may be obtained by mixing the raw material crude drugs and then extracting with a solvent, and the extracts obtained by extracting each raw material crude drug with a solvent are mixed at a predetermined ratio. It may be obtained by the above.
  • the composition of the present invention contains an effective amount of Daikenchuto extract to increase the occupancy rate of Bifidobacterium spp. And Coprococcus spp. In the intestinal flora, and also to increase the occupancy rate of Fusobacterium. The occupancy rate of bacteria can be reduced.
  • the effective amount (intake amount) of the Daikenchuto extract can be appropriately set according to various conditions such as the weight, age, sex, and symptoms of the ingestor. For example, a soft extract of the Daikenchuto extract.
  • the extract granules may be 0.1 to 15 g / day, and if it exceeds 15 g / day, it may lead to diarrhea, and if it is less than 0.1 g / day, the effect may not be obtained.
  • the daily intake of Daikenchuto extract may be, for example, 0.1 to 6 g or 0.1 to 3 g, or 0.5 to 4 g or 0.5 to 2 g.
  • the daily intake of the above Daikenchuto extract is obtained from the raw material crude drug consisting of (1) Japanese pepper or Japanese pepper 0.5 to 6 g, (2) Ginseng 0.5 to 6 g, and (3) Dried ginger 1 to 12 g. It is an amount corresponding to the extract to be obtained. That is, as the raw material crude drug for obtaining the above-mentioned daily amount of Daikenchuto extract, for example, a raw material crude drug consisting of 0.5 to 6 g of Japanese pepper or Japanese pepper, 0.5 to 6 g of carrot, and 1 to 12 g of dried ginger.
  • It may be a crude drug consisting of 0.5 to 2 g of Japanese pepper, 0.5 to 2 g of ginger, and 1 to 4 g of dried ginger, and 1 to 1.5 g of Japanese pepper and 1 to 1.5 g of ginger.
  • And 1.5 to 2.5 g of dried ginger may be a raw material crude drug.
  • the composition of the present invention is not limited to once a day, but can be ingested (taken) in multiple divided doses. That is, the composition of the present invention may be ingested once a day, or may be ingested in a plurality of times, for example, twice, three times or four times. When taking multiple times, the total daily dose may be the daily dose.
  • the timing of ingestion of the composition of the present invention is not particularly limited, and in the case of ingestion once a day, after waking up (within about 30 minutes from waking up time), before meals (about 30 minutes to 60 minutes before meals), and between meals.
  • composition of the present invention can be expected to have a desired effect even if it is ingested once, but in order to obtain a more sustainable effect, it is 1 week or more, preferably 2 weeks or more, more preferably 3 weeks or more. Particularly preferably, it can be continuously ingested for 4 weeks or longer, 8 weeks or longer, 3 months or longer, 6 months or longer, and 1 year or longer.
  • increasing the occupancy rate of Bifidobacterium in the intestinal flora means “Bifidobacterium in the intestinal flora after ingestion of the composition of the present invention”.
  • Occupancy rate is 0.5% or more, for example, 1% or more, 1.5% or more, 2% or more, 2.5% or more, 3% or more, 3.5% or more, 4% compared to before ingestion. As mentioned above, it means that the increase is 4.5% or more, 5% or more, or 5.5% or more.
  • the occupancy rate of bifidobacteria in the intestinal flora after ingestion of the composition of the present invention is 120% or more of the occupancy rate of bifidobacteria in the intestinal flora before ingestion. , 130% or more, 150% or more, 180% or more, or 200% or more. This does not apply to subjects who do not have Bifidobacterium spp.
  • incrementing the occupancy rate of Gut microbiota in the intestinal flora means the occupancy of Gut microbiota in the gut microbiota after ingestion of the composition of the present invention.
  • the rate is 0.25% or more, for example, 0.5% or more, 0.75% or more, 1% or more, 1.25% or more, 1.5% or more or 1.75% or more compared to before ingestion. Means to increase.
  • the occupancy rate of Gut microbiota in the intestinal flora after ingestion of the composition of the present invention is 120% or more, 130% or more of the occupancy rate of Gut microbiota in the gut microbiota before ingestion. , 150% or more, 180% or more, or 200% or more. This does not apply to subjects who do not have Coccoccus spp.
  • reducing the occupancy rate of Fusobacterium in the intestinal flora means that the occupancy rate of Fusobacterium in the intestinal flora after ingestion of the composition of the present invention is defined as. 0.5% or more, for example, 1% or more, 1.5% or more, 2% or more, 2.5% or more, 3% or more, 3.5% or more or 4% or more decrease compared to before ingestion. Means.
  • the occupancy rate of Fusobacterium in the intestinal flora after ingestion of the composition of the present invention is 90% or less, 80% or less, 70% of the occupancy rate of Fusobacterium in the intestinal flora before ingestion. It may be% or less, 60% or less, or 50% or less. This does not apply to subjects who do not have Fusobacterium spp.
  • the intestinal flora means a bacterium existing in the intestine (intestinal bacterium), and all detectable bacteria, for example, Bifidobacterium spp., Clostridium spp., Fusobacterium spp. Includes Clostridium spp., Drea spp., And Osirospira spp. Detection of gut microbiota can be performed by commonly known methods or commercially available kits. As an example, using feces as a sample, DNA in feces before and after ingestion of the composition of the present invention was purified, 16S rRNA V3-V4 region was amplified, and sequence analysis was performed using the next-generation sequencer MiSeq.
  • OTU operation taxonomy unit
  • composition of the present invention can be used for therapeutic or non-therapeutic applications.
  • composition of the present invention can be applied to mammals including humans, monkeys, mice, rats, rabbits, dogs, cats, horses, cows, pigs and the like, preferably humans.
  • composition of the present invention is effective for treatment, prevention or improvement by increasing the occupancy rate of Bifidobacterium spp. In the intestinal flora, increasing the occupancy rate of Coprococcus spp., And decreasing the occupancy rate of Fusobacterium spp. It can be used for the treatment, prevention or amelioration of a disease or symptom.
  • Inflammatory bowel diseases such as ulcerative colitis, Crohn's disease
  • allergic diseases eg, food allergies, pollinosis, asthma, allergic rhinitis, drug allergies, atopic dermatitis, tick allergies
  • diarrhea and constipation etc.
  • Intestinal diseases colon cancer, diabetes, depression, periodontal disease, Remière syndrome, skin ulcers, and other diseases thought to be caused by intestinal symbiotic imbalance (Dysbiosis) (eg, hypersensitivity intestinal syndrome, small intestinal bacterial abnormalities)
  • examples thereof include proliferative disorders (SIBO), pseudomembranous colitis (Crostridium difficile enteritis), obesity, allergic diseases, mental diseases such as autism, and polysclerosis).
  • composition of the present invention may be a food composition, a pharmaceutical composition or a quasi-drug, or may be used as an additive for foods, feeds and the like.
  • the composition of the present invention may consist only of Daikenchuto extract, and may contain components other than Daikenchuto extract.
  • the blending amount of Daikenchuto extract in the composition of the present invention can be appropriately set according to the form, dosage form, symptoms and the like, and is typically 0.1 to 100% by mass, preferably 0. It can be 1 to 99.9% by mass, more preferably 0.1 to 50% by mass, and particularly preferably 0.1 to 30% by mass.
  • composition of the present invention is not particularly limited in its form, and may have a pharmaceutical form such as jelly, powder, granule, tablet, capsule, liquid, suspension, milky liquid or the like.
  • the method for ingesting (administering) the composition of the present invention is preferably oral administration.
  • administration other than oral administration is also possible.
  • the composition of the present invention may contain a base for the purpose of efficient transportation to the intestine.
  • a general gelling agent is used, and an appropriate storage stability is required. Therefore, a base other than gelatin is preferable.
  • a gelling agent for example, carrageenan, locust bean gum, xanthan gum, polyacrylic acid, carob bean gum and the like are preferable.
  • the food composition of the present invention is intended for health, health maintenance, promotion, etc., and is preferably a food composition as prebiotics, for example, health foods, functional foods, nutritional supplements, supplements, etc.
  • prebiotics for example, health foods, functional foods, nutritional supplements, supplements, etc.
  • examples include foods for specified health use, foods with nutritional function, foods with functional claims, foods for infants, foods for pregnant women, and foods for the sick.
  • additional ingredients can be added to the food composition as needed.
  • a food material having functionality can be arbitrarily blended for the purpose of exerting a complex effect.
  • various crude drugs other than Daikenchuto extract, various probiotics, prebiotics, various oligosaccharides, vitamins, minerals and other nutritional components, and other known functional food materials can be appropriately blended.
  • food raw materials used in ordinary foods can be arbitrarily blended.
  • various general ingredients starch, gelatin, carboxymethyl cellulose, Arabic gum, locust bean gum, tragant gum, karaya gum, konjac glucomannan, xanthan gum, agar, carrageenan, polyacrylic acid, carob bean gum, alginic acid, cyclodextrin and other gelling agents.
  • the base vegetable fats and oils, animal fats and oils, processed fats and oils, seasonings, sweeteners, spices, coloring agents, preservatives, antioxidants, water and the like can be arbitrarily blended.
  • the food composition includes all foods and drinks that can be ingested by animals (including humans).
  • the type of food composition is not particularly limited, and is, for example, dairy products; fermented foods (yogurt, cheese, etc.); beverages (soft beverages such as coffee, juice, tea beverages, carbonated beverages, dairy beverages, lactic acid bacteria beverages, etc.
  • Such foods can be provided as dishes at business stores, or can be provided in a general distribution form by taking a prepared food, a retort pouch food, a frozen food, a packaging form of other general food compositions, or the like.
  • the method for producing the food composition of the present invention is not particularly limited, and a known method can be appropriately followed.
  • the administration unit form thereof is not particularly limited and can be appropriately selected, and examples thereof include tablets, capsules, granules, liquids, powders, and jellies.
  • the composition of the present invention may be a pharmaceutical composition or a non-pharmaceutical product, and in this case, it may consist only of Daikenchuto extract, which is pharmaceutically acceptable in addition to Daikenchuto extract.
  • Tablets including uncoated tablets, sugar-coated tablets, film-coated tablets, effervescent tablets, chewable tablets, troches, etc.), capsules, pills, powders (powder), along with non-toxic carriers, diluents or excipients. It can be prepared in the form of fine granules, granules, liquids, suspensions, emulsions, jellies, syrups, pastes, etc. to be pharmaceutical preparations or non-pharmaceutical products.
  • Pharmaceutically acceptable non-toxic carriers include, for example, binders, additives, fragrances, buffers, thickeners, colorants, stabilizers, emulsifiers, dispersants, suspending agents, preservatives and the like. Will be.
  • the method for administering the pharmaceutical composition and quasi-drug of the present invention is not particularly limited, and is, for example, oral administration, rectal administration, enteral administration, oral administration, intraarterial administration, intravenous administration, transdermal administration, or the like. be able to.
  • the composition of the present invention is preferably a food composition from the viewpoint of easy availability.
  • the food composition, pharmaceutical composition, or non-pharmaceutical product of the present invention increases the occupancy rate of Bifidobacterium spp. In the intestinal flora, and increases the occupancy rate of Coprococcus spp. , Decreasing the occupancy rate of Fusobacterium spp., Improving the intestinal environment, increasing the occupancy rate of butyric acid-producing bacteria in the intestinal flora, etc. may be attached.
  • the packaging form is not particularly limited as long as it can contain a certain amount, and examples thereof include bags, wrapping paper, paper containers, soft bags, cans, bottles, and capsules.
  • the present invention comprises administering an effective amount of Daikenchuto extract to a subject in need thereof, and the occupancy rate of Bifidobacterium spp. And Coprococcus spp. In the intestinal flora.
  • a method for increasing and reducing the occupancy rate of Fusobacterium spp. treats, prevents or ameliorate diseases and conditions that can be treated, prevented or ameliorated by increasing the occupancy rate of Bifidobacterium spp., Increasing the occupancy rate of Coprococcus spp., And decreasing the occupancy rate of Fusobacterium spp. It may be a method.
  • the present invention also increases the occupancy rate of Bifidobacterium and Coprococcus in the intestinal flora of an effective amount of Daikenchuto extract, and also increases the occupancy of Fusobacterium. Provided for use in the manufacture of compositions for reducing.
  • the present invention further increases the occupancy rate of Bifidobacterium spp. And Coprococcus spp. In the intestinal flora, and reduces the occupancy rate of Fusobacterium spp. Provide the use of Nakato extract.
  • Example 1 Human fecal anaerobic culture test (preparation of composition)
  • Commercially available Japanese pepper manufactured by Ryu Fukuda Co., Ltd.
  • ginseng Ginseng; manufactured by Keien Japan Co., Ltd.
  • dried ginger Zhejiang Keimatsu Pharmaceutical Co., Ltd., China
  • a soft extract of ginseng was prepared by boiling and extracting with% hydrous ethanol, filtering, concentrating, and sterilizing. 1.25 g of Daikenchuto soft extract was obtained for 1 g of Japanese pepper, 1 g of ginseng, and 2 g of dried ginger.
  • feces collected from four donors F32 (32-year-old female), F42b (42-year-old female), M39 (39-year-old male), M41 (41-year-old male)
  • F32 32-year-old female
  • F42b 42-year-old female
  • M39 39-year-old male
  • M41 41-year-old male
  • Daikenchuto extract was added to each fecal incubator at 0.5% by mass at the start of culturing.
  • fecal incubators to which Daikenchuto extract was not added were prepared and a culture test was conducted.

Abstract

La présente invention a pour objet de produire une composition ayant un effet avantageux sur la flore intestinale, basée sur l'étude des effets du Daikenchuto sur des genres spécifiques de bactéries dans la flore intestinale. Une composition selon la présente invention comprend une quantité efficace d'extrait de Daikenchuto, et est destinée à augmenter l'occupation de la flore intestinale par des bactéries du genre Bifidobacterium et des bactéries du genre Coprococcus, et à réduire l'occupation de la flore Intestinale par des bactéries du genre Fusobacterium.
PCT/JP2021/030999 2020-08-28 2021-08-24 Composition pour modifier l'occupation de la flore intestinale par de genres spécifiques de bactéries WO2022045138A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-144382 2020-08-28
JP2020144382A JP2022039387A (ja) 2020-08-28 2020-08-28 腸内菌叢中の特定の細菌属の占有率を変化させるための組成物

Publications (1)

Publication Number Publication Date
WO2022045138A1 true WO2022045138A1 (fr) 2022-03-03

Family

ID=80353958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/030999 WO2022045138A1 (fr) 2020-08-28 2021-08-24 Composition pour modifier l'occupation de la flore intestinale par de genres spécifiques de bactéries

Country Status (3)

Country Link
JP (1) JP2022039387A (fr)
TW (1) TW202227115A (fr)
WO (1) WO2022045138A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017175999A (ja) * 2016-03-29 2017-10-05 株式会社ツムラ 大建中湯の効果予測方法および投与量決定方法
JP2020078273A (ja) * 2018-11-13 2020-05-28 株式会社サイキンソー 腸内ｄｙｓｂｉｏｓｉｓ判定システム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017175999A (ja) * 2016-03-29 2017-10-05 株式会社ツムラ 大建中湯の効果予測方法および投与量決定方法
JP2020078273A (ja) * 2018-11-13 2020-05-28 株式会社サイキンソー 腸内ｄｙｓｂｉｏｓｉｓ判定システム

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
.: "Organizer planning seminar / exhibitor presentation information posted on the "ifia", HFA JAPAN 2017, IFIA, JP, 24 May 2017 (2017-05-24), JP, XP055905346, Retrieved from the Internet <URL:https://www.ifiajapan.com/2017/seminar> [retrieved on 20220325] *
HOSHINO NOBUAKI, KAWADA KENJI, HIDA KOYA, WADA TOSHIAKI, TAKAHASHI RYO, YOSHITOMI MAMI, SAKAI YOSHIHARU: "Effect of Daikenchuto (TJ-100) on gastrointestinal symptoms following laparoscopic colectomy in patients with colon cancer: study protocol for a randomized controlled trial", TRIALS, vol. 18, no. 1, 1 December 2017 (2017-12-01), XP055905188, DOI: 10.1186/s13063-017-2307-7 *
TOKIWA PHYTOCHEMICAL CO., LTD.-): "Full-scale supply of "Japanese-Chinese plant complex extract" applying the Chinese medicine prescription to general food field ", THE HEALTH INDUSTRY NEWS, INFORMA MARKETING SOTSU JAPAN SPECIAL COMPANY, JP, 15 May 2018 (2018-05-15), JP, XP055905340, Retrieved from the Internet <URL:https://www.kenko-media.com/health_idst/archives/9760> [retrieved on 20220325] *
TSUMURA DAIKENCHUTO: "TSUMURA Daikenchuto Extract Granules for Ethical Use", PHARMACEUTICAL INTERVIEW FORM, 9TH EDITION, TSUMURA, JP, 1 November 2014 (2014-11-01), JP, XP055905187, Retrieved from the Internet <URL:https://medical.tsumura.co.jp/products/100/pdf/100-if.pdf> [retrieved on 20220325] *

Also Published As

Publication number Publication date
TW202227115A (zh) 2022-07-16
JP2022039387A (ja) 2022-03-10

Similar Documents

Publication Publication Date Title
CN107496850B (zh) 一种调节肠道微生态制剂的配方及应用
CN115074274B (zh) 含乳酸菌的组合物及其用途
WO2017130859A1 (fr) Inhibiteur de l&#39;apoptose des cellules neuronales
JP2018153182A (ja) ラクトバチルスプランタルムｔｃｉ３７８、およびそれを用いた脂肪の減少および胃腸機能の改善における使用
CN107530387B (zh) 含有双歧杆菌和十字花科蔬菜的经口组合物
CN109315769A (zh) 一种用于改善人体肠内环境的组合物及其制备方法
WO2020118576A1 (fr) Utilisation de lactobacillus plantarum twk10 dans la préparation d&#39;une composition pour une résistance à une inflammation post-exercice ou pour réduire la graisse corporelle
KR102305931B1 (ko) 혈액순환 개선 및 면역력 증진 효능을 가지는 천연 추출물을 포함하는 식품 조성물
CA2324399A1 (fr) Composition alimentaire et utilisation connexe permettant d&#39;abaisser les taux de cholesterol humain
CN104146312B (zh) 调理胃肠功能的保健品
JP2023075284A (ja) 経口組成物
KR102037897B1 (ko) 케피어 유래 유산균 및 포도씨 분말을 포함하는 비만의 예방 또는 치료용 조성물
JP7467804B2 (ja) 腸内菌叢改善用組成物
WO2022045138A1 (fr) Composition pour modifier l&#39;occupation de la flore intestinale par de genres spécifiques de bactéries
CN110279720B (zh) 一种五谷虫炮制品及其在调节肠道菌群中的应用
KR20130071203A (ko) 변비 개선용 조성물 및 이의 제조방법
KR101421677B1 (ko) 장 기능 및 변비 개선 효과를 나타내는 유산균을 이용한 치커리 화이바 발효물의 제조방법
CN115702001A (zh) 用于抑制或改善抑郁的组合物
KR20220058176A (ko) 장내 균총 개선용 프리바이오틱스 조성물
JP2007054081A (ja) ハスの破砕物および／または抽出物と、乳酸菌とを含む抗アレルギー用食品
WO2020179810A1 (fr) Composition permettant d&#39;augmenter l&#39;occupation de faecalibacterium dans la flore intestinale
KR102609638B1 (ko) 미역귀 추출물을 유효성분으로 포함하는 장내 균총 개선용 조성물
JP7257665B2 (ja) 経口組成物
CN108719752A (zh) 一种富含营养成分的功能性面粉
JP6173850B2 (ja) 筋肉増量剤、運動併用時の筋肉増量剤、及び筋肉増量用の飲食品

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21861563

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21861563

Country of ref document: EP

Kind code of ref document: A1